Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious procedure, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://ericho087uxz0.weblogco.com/profile